

# Ultra-Comprehensive Genomic Profiling With the OncoExTra™ Test

The OncoExTra test is an ultra-comprehensive genomic profiling assay that incorporates tumor whole-exome (DNA) and whole-transcriptome\* (RNA) sequencing with paired tumor-normal analysis to identify alterations/biomarkers in individuals diagnosed with advanced cancers. These insights can help inform targeted therapy options and clinical trials eligibility.

With ~20,000 genes profiled, an assessment of key immuno-oncology signatures (TMB & MSI), clinical trial availability, and Medicare coverage, the OncoExTra test is designed to provide actionable insights to help inform clinical decision making for a breadth of solid tumor types.

## All solid tumors including:

### Lung



### Breast



### Colon



### Bladder



## In a multicenter retrospective analysis of 1,261 patients tested with the OncoExTra test:†

- 75 actionable fusions were detected (5.9%).
- 41% of actionable fusions were supported by RNA sequencing alone and were not detected at the DNA level.
- 100% of RNA-only detected fusions were clinically actionable.

\*Whole-transcriptome sequencing with select variants reported in New York State

# Easy to Interpret Clinical Report to Guide Therapy Selection

**oncoExTra™**

**EXACT  
SCIENCES**

Report Date: MM/DD/YYYY

Patient: Sample Patient	Ordering Client: Medical Center	<b>Results Snapshot</b> Analytes sequenced: DNA+RNA+IHC Actionable Targets: 5    IHC Tested: 1 TMB: Intermediate    PD-L1: See Below MSI: Stable Clinical Trials: Yes	
Sex at Birth: Female	Specimen Type: FFPE Block		
DOB: MM/DD/YYYY	Specimen Site: Lung		
Medical Record #: MR 000000	Tumor Collection Date: MM/DD/YYYY		
Client Accession #: CA 000000	Normal Collection Date: MM/DD/YYYY		
Ordering Physician: Sample Physician	Received Date: MM/DD/YYYY		

Diagnosis: **Lung Cancer**

KEY BIOMARKER FINDINGS				
KEY BIOMARKERS	FDA-APPROVED DRUGS -for patient's cancer <sup>1</sup>	FDA-APPROVED DRUGS -for another cancer <sup>1</sup>	DRUGS PREDICTED NON-BENEFICIAL/ REDUCED BENEFIT	POTENTIAL CLINICAL TRIALS
TUMOR GENOMIC ALTERATIONS				
ARID1A (S2249*)				Yes
CD74/ROS1 (Fusion)	crizotinib, entrectinib	cabozantinib, ceritinib, lorlatinib		Yes
NF1 (Q369*)		binimetinib, everolimus, temsirolimus, trametinib		Yes
TP53 (I195T)				Yes
TUMOR MUTATION BURDEN (TMB)				
INTERMEDIATE (8 mut/Mb)				No
MICROSATELLITE STATUS (MSI)				
STABLE				No
IHC RESULTS				
PD-L1 (22C3): Low	atezolizumab, durvalumab, nivolumab, nivolumab + ipilimumab, pembrolizumab	dostarlimab-gxly		
HIGH INTEREST BIOMARKERS				

As part of the OncoExTra test, key biomarkers relevant in the patient's tumor type have been assessed: **NTRK1, NTRK2, NTRK3, RET, BRAF, ALK, EGFR, ERBB2, KRAS, MET, ROS1, PD-L1**. If clinically pertinent event(s) in these biomarkers have been identified, the biomarker(s) will appear within the 'Key Biomarker Findings' section of the report. If Biomarkers from this list do not appear, clinically pertinent event(s) have not been identified or fell outside of the OncoExTra reporting thresholds (please see Disclaimer Limitations information).

<sup>1</sup>The prescribing information for the FDA-approved therapeutic option may not include the associated Key Biomarker

Alteration(s) Detected & Approved Therapies

MSI Status

High Interest Biomarkers


Genomic Snapshot with Key Findings

Clinical Trial Options

TMB Status

IHC Results<sup>†</sup>

To Learn More: [OncoExTra.com](https://oncoextracom.com) | To Order: [OncoExTra.com/order](https://oncoextracom.com/order)



**Reference:** 1. White T, Szelinger S, LoBello J, et al. Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra™. *Oncotarget*. 2021;12:726-739.  
<sup>†</sup>IHC testing not currently available in New York State

OncoExTra has been validated according to the guidelines set forth by the New York State Department of Health. Whole exome (DNA) events have been validated to include point mutations, indels, and copy number alterations, as well as MSI analysis and TMB calculation. Whole transcriptome (RNA) has been validated to report on select fusion genes and special transcripts.

OncoExTra is a trademark of Genomic Health, Inc., a wholly-owned subsidiary of Exact Sciences Corporation. Exact Sciences is a registered trademark of Exact Sciences Corporation.  
 © 2023 Genomic Health, Inc. All rights reserved. M-US-GEM-00067\_1123